ClinicalTrials.govcontrolled
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Met
ClinicalTrials.gov study NCT03653507. IPD Sharing: YES. Countries: 18. Publications: 2.
ShareScore
36/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 12
- Access
- 4
- Reuse readiness
- 0
- Engagement
- 8